The $125 billion question: how will the ACA affect cancer survivors?
In 2010, the total cost of cancer care in the United States reached $125 billion. Cancer patients are also living longer today, which is further increasing the cost of their continued care. As the health insurance exchanges have opened and heated debate about the Affordable Care Act (ACA) continues, many questions remain, including the $125 billion question: “How will the ACA affect the most expensive disease: cancer?”
Two clinical trials test novel combination therapies for brain and central nervous system cancers
Researchers at VCU Massey Cancer Center are conducting two clinical trials testing novel combination therapies for the treatment of brain and central nervous system cancers. The phase 1 and phase 2 clinical trials are both based on translational research performed at Massey by Paul Dent, Ph.D., Universal Corporation Chair in Cancer Cell Signaling and member of the Cancer Cell Signaling research program at VCU Massey as well as professor of biochemistry and molecular biology at VCU School of Medicine.
Clinical trial tests promising immunotherapies for advanced lung cancer
Sherman Baker Jr., M.D., medical oncologist and member of the Developmental Therapeutics research program at VCU Massey Cancer Center, is spearheading a phase 3 clinical trial testing two immunotherapy drugs, MEDI4736 and tremelimumab, for the treatment of patients with advanced lung cancer. The goal of the study is to determine whether MEDI4736 combined with tremelimumab or MEDI4736 by itself is more effective than traditional chemotherapy treatment to treat advanced lung cancer.
Massey researcher awarded $3 million to study the effect of blood cell stimulation on the development of adolescent leukemia and bone marrow disorders
Massey program leader, researcher and physician Seth Corey M.D., M.P.H., was awarded more than $3 million in grant funding from the National Heart, Lung and Blood Institute (NHLBI) for a four-and-a-half-year study on the evolution of a blood cell deficiency to pre-leukemia. The research aims to determine whether a common treatment for the condition acts as a contributor to the development of leukemia or other life-threatening bone marrow disorders.
A second first birthday
Six months after her original cancer diagnosis, Ann Moore sat in a clinic exam room anticipating the results from her CT scan. In February 2015, she had received the last of 18 weeks worth of chemotherapy treatment for stage IV ovarian cancer, and now waited anxiously to hear if it had been effective.
VCU Massey researchers uncover process that drives prostate cancer metastasis
Researchers at VCU Massey Cancer Center have uncovered a novel function of the gene PLK1 (polo-like kinase 1) that helps prostate cancer cells metastasize (spread) to other parts of the body. This mechanism highlights new potential targets for cancer therapies and challenges the previous understanding of PLK1’s role in cancer growth and progression.